Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Corsair Gaming Inc (CRSR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Corsair Gaming Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $281.81 (market cap $39.89B), while Corsair Gaming Inc trades at $9.41 (market cap $1.03B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 38.7× Corsair Gaming Inc's market cap, and Corsair Gaming Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CRSR | |
|---|---|---|
Market Cap | $39.89B | $1.03B |
Sector | Health | Technology |
52-Week High | $491.22 | $12.14 |
52-Week Low | $278.09 | $4.58 |
Enterprise Value | $38.15B | $1.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Corsair Gaming (CRSR) trades at $9.66, up 1.15% with a bullish technical outlook. The stock shows mixed fundamentals with a high P/E ratio of 107.33 but attractive P/S of 0.71, while recent earnings beats and new AI product launches drive optimism. Revenue remains stable around $1.5B, though profitability is inconsistent with a net margin of just 0.49%.
Corsair presents a speculative opportunity with strong product innovation but faces execution risks. Analyst consensus is cautious with a $9 price target below current levels. The company's pivot to AI hardware and gaming partnerships offers growth potential, but thin margins and competitive pressures require careful monitoring for sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Corsair Gaming Inc
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →
